Targeted Drug Therapy Testing
Targeted Drug Therapy Testing - Related Videos
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
0 Views •
Cited by 4 •
2016
Methods to evaluate the efficacy and toxicity of RNA molecules targeting post-integration steps of the HIV-1 replication cycle are described. These methods are useful for screening new molecules and optimizing the format of existing ones.
10:13
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
0 Views •
Cited by 29 •
2015
Many types of human brain tumors are localized to specific regions within the brain and are difficult to grow in culture. This protocol addresses the role of tumor microenvironment and investigates new drug treatments by analyzing fluorescent primary brain tumor cells growing in an organotypic mouse brain slice.
11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
0 Views •
Cited by 4 •
2013
Acquired resistance to antibiotics is a major public healthcare problem and is presently ranked by the WHO as one of the greatest threats to human life. Here we describe the use of cantilever technology to quantify antibacterial resistance, critical to the discovery of novel and powerful agents against multidrug resistant bacteria.
01:28
Drug Therapy
0 Views •
2025
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations. Antianxiety Medications
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
FAQs
The testing process links drug activity to evidence that the intended target is affected. Biomarkers, including genetic alterations or proteins, can indicate whether the relevant biological feature is present, while laboratory assays, patient-derived samples, or clinical measurements assess target engagement and treatment response. Comparing these findings with resistance signals helps clarify whether the drug is acting through the expected disease-related pathway.
Genetic alterations and proteins can distinguish patients or disease samples according to features relevant to a medicine’s activity. Their measurement creates a biological link between the treatment and the disease process being investigated. This information may help explain different patient responses and support more informed evaluation of whether a particular treatment is appropriate for a defined molecular context.
Targeted therapy testing emphasizes biological specificity by asking whether a medicine affects a defined molecular target associated with the disease process. Nonspecific treatment does not rely on the same degree of target-linked evaluation. This distinction allows testing to examine target engagement, biomarker-associated response, and potential resistance rather than assessing treatment effects without that molecular context.
Evaluation may combine laboratory assays, patient-derived samples, and clinical measurements. Laboratory assays can examine drug activity or target engagement, patient-derived samples can connect those findings to an individual’s disease biology, and clinical measurements can assess treatment response. Using these sources together supports a more informative view of how molecular evidence relates to observed outcomes.
Targeted drug therapy testing can inform treatment selection, dose evaluation, and regimen evaluation. It is also useful when designing clinical studies because molecular and clinical measurements can help investigators assess response more precisely. By connecting treatment decisions and study design to target-related evidence, the approach supports therapies and trials that reflect biological differences among patients.
The approach supports precision medicine by examining why patients respond differently to medicines aimed at defined molecular features. Testing can associate response with a biomarker and identify evidence of potential resistance, providing a basis for interpreting variation in treatment outcomes. These findings can guide treatment selection and help clinical studies evaluate responses in biologically meaningful groups.